Decagon Asset Management’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Decagon Asset Management’s Portfolio OACC Stock Details OACC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Buy	1,002,427 +326,790	+48%	+$3.48M	2.75%	10
2025 Q4	$7.15M	Buy	675,637 +31,316	+5%	+$331K	2.75%	11
2025 Q3	$6.77M	Buy	644,321 +26,305	+4%	+$275K	3.42%	11
2025 Q2	$6.46M	Sell	618,016 -98,930	-14%	-$1.03M	4.21%	9
2025 Q1	$7.33M	Buy	716,946 +7,016	+1%	+$70.4K	5.26%	8
2024 Q4	$7.07M	Buy	+709,930	New	+$7.08M	3.22%	14

Other funds holding OACC

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

FBCM

Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BGIM

Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Decagon Asset Management's OACC Position: Q1 2026 in Review

Decagon Asset Management increased its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 48% in Q1 2026, buying an estimated $3.48M and bringing the position to 1,002,427 shares worth $10.6M. The position accounts for 2.75% of the portfolio, ranked #10.

Decagon Asset Management first reported a position in OACC in Q4 2024 and has held it in 6 quarters since. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

Decagon Asset Management held 1,002,427 shares of Oaktree Acquisition Corp III Life Sciences worth $10.6M as of Q1 2026.
Decagon Asset Management bought 326,790 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $3.48M.
Oaktree Acquisition Corp III Life Sciences made up 2.75% of Decagon Asset Management's portfolio in Q1 2026, its #10 holding.
Decagon Asset Management first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and has held it in 6 quarters since.
51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Decagon Asset Management's 13F filing for Q1 2026, filed 15 May 2026.